Thymosin Alpha-1 (Tα1) – User Manual & Dosage Protocol Guide

Thymosin Alpha-1 (Tα1) is a 28–amino acid peptide derived from prothymosin alpha. It is studied for its role in immune modulation and enhancement of T-cell function. In several countries, Thymosin Alpha-1 (under brand names such as Zadaxin®) has been used in regulated clinical settings for specific immune-related indications.

Research Applications

• T-cell activation studies
• Immune modulation research
• Chronic viral infection models
• Vaccine response enhancement investigations
• Oncology adjunct research models
• Inflammatory pathway modulation

Disclaimer: Thymosin Alpha-1 may be approved for limited indications in certain countries. Use outside approved medical supervision is not authorized. The following reflects clinical and investigational reference information.

Lyophilized Powder

Freeze-dried Thymosin Alpha‑1 intended for reconstitution prior to use in research or clinical settings.

Pre‑filled Syringe

A ready-to-use injectable formulation, available where provided by the manufacturer.

Typical Vial Strengths

Common strengths include 1.6 mg and 3.2 mg.

Thymosin Alpha-1 is studied for its ability to:

• Enhance T-lymphocyte differentiation and maturation
• Promote CD4+ and CD8+ T-cell activity
• Increase natural killer (NK) cell function
• Modulate cytokine production
• Support immune response regulation

It acts primarily as an immune response modifier rather than a direct stimulant.

Chronic Viral Hepatitis (Clinical Use in Some Countries)

• 
  Administration: Subcutaneous (SC)
  
• 
  Typical Range: 1.6 mg
  
• 
  Frequency: Twice weekly
  

Oncology Adjunct / Immune Support (Investigational Use)

• 
  Administration: Subcutaneous (SC)
  
• 
  Typical Range: 1.6 mg
  
• 
  Frequency: 2–3 times weekly
  

Immune Modulation Research

• 
  Administration: Subcutaneous (SC)
  
• 
  Typical Range: 1.6 mg
  
• 
  Frequency: 1–2 times weekly
  

Duration

Treatment commonly ranges from 6–24 weeks, depending on the clinical objective.

Important

Dosing must be supervised by a licensed healthcare professional and individualized based on immune markers and physician oversight.

Initiation

A 2–4 week phase used to monitor baseline immune markers before starting active treatment.

Active Treatment

Typically 6–24 weeks, focused on modulating immune responses.

Maintenance (if indicated)

Duration is physician-directed, aimed at providing sustained immune support.

Supplies

• Sterile water for injection (if not included)
• Sterile syringe
• Alcohol swabs

Example Reconstitution

If using 1.6 mg vial:

Add 1 mL sterile water
→ Final concentration = 1.6 mg/mL

Swirl gently to dissolve (do not shake).
Refrigerate at 2–8°C after reconstitution.
Use within timeframe specified by manufacturer.

Subcutaneous Injection

• Common sites: abdomen or thigh
• Clean site with alcohol
• Inject slowly
• Rotate injection sites

Administration is typically performed twice weekly in many clinical protocols.

Lyophilized Powder

Store refrigerated or according to manufacturer instructions, with a shelf life up to the expiration date.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within the recommended period.

Protection Guidelines

Protect from heat, light, and contamination. Do not freeze unless specifically instructed.

Thymosin Alpha-1 is generally well tolerated in clinical studies.

Possible Side Effects

• Mild injection-site irritation
• Fatigue
• Headache
• Mild flu-like symptoms (rare)

Suggested Monitoring

• Complete blood count (CBC)
• Immune markers (CD4/CD8 ratio)
• Liver function tests (in hepatitis protocols)

Use must be supervised by a healthcare provider.

Peptide: Thymosin Alpha-1
Category: Immune Modulator
Delivery: Subcutaneous injection
Typical Clinical Range: 1.6 mg, 1–3 times weekly
Duration: 6–24 weeks depending on indication
Storage: Refrigerated after reconstitution